Drug Treatment Patterns of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents in Germany: Results from a Large Population-Based Cohort Study

被引:54
作者
Garbe, Edeltraut [1 ,2 ]
Mikolajczyk, Rafael T. [1 ]
Banaschewski, Tobias [3 ]
Petermann, Ulrike [4 ]
Petermann, Franz [4 ]
Kraut, Angela A. [1 ]
Langner, Ingo [1 ]
机构
[1] BIPS Inst Epidemiol & Prevent Res, D-28359 Bremen, Germany
[2] Univ Bremen, Fac Human & Hlth Sci, D-28359 Bremen, Germany
[3] Heidelberg Univ, Med Fac Mannheim, Dept Child & Adolescent Psychiat & Psychotherapy, Cent Inst Mental Hlth, D-6800 Mannheim, Germany
[4] Univ Bremen, Ctr Clin Psychol & Rehabil, D-28359 Bremen, Germany
关键词
DEFICIT HYPERACTIVITY DISORDER; METHYLPHENIDATE PRESCRIPTIONS; RELEASE METHYLPHENIDATE; HYPERKINETIC DISORDER; PREVALENCE; ADHD; REPRESENTATIVITY; DISCONTINUATION; GUIDELINE; DIAGNOSES;
D O I
10.1089/cap.2012.0022
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: Despite a substantial increase in total methylphenidate (MPH) prescriptions in Germany over the last 20 years, and the introduction of modified release MPH (MR MPH) and atomoxetine (ATX), remarkably little is known about treatment patterns of attention- deficit/hyperactivity disorder (ADHD) in individual patients. Methods: Usage patterns of ADHD drugs in children and adolescents in Germany were analyzed using data from one large German health insurance including >7,200,000 members. Of those, 6210 ADHD patients newly diagnosed in 2005 were followed for a maximum of 4 years. Kaplan-Meier estimates were calculated for onset and discontinuation of ADHD drug treatment. Predictors of time until drug treatment initiation were assessed by Cox regression. Results: During follow-up, 52.0% of ADHD subjects (53.4% of boys, 47.5% of girls) received ADHD drug treatment. The majority of them (91.6%) were started on MPH, with immediate release MPH (IR MPH) being the initial treatment choice in 75.3%. In these subjects, change to drug treatment with MR MPH in the first year occurred in 48% by switch or addition. Significant predictors of drug treatment were behavioral and emotional disorders (HR = 1.13; 95% CI 1.03-1.24) and a diagnosis of ADHD with conduct disorder (HR = 1.21, 95% CI 1.12-1.32), whereas young age showed a protective effect. After 6, 12, and 24 months of treatment initiation, 22.4%, 43.4%, and 66.3% of treated girls, and 17.8%, 36.1%, and 54.1% of treated boys had discontinued ADHD treatment. Conclusion: Drug treatment of ADHD was relatively common in Germany and more frequent in boys than in girls. IR MPH was the predominant treatment choice at treatment initiation. Approximately 20% of treated subjects discontinued drug treatment within the first 6 months, with girls stopping drug treatment earlier than boys. The reasons for early drug discontinuation need to be further explored.
引用
收藏
页码:452 / 458
页数:7
相关论文
共 29 条
[1]  
[Anonymous], MAN ATT DEF HYP DIS
[2]   Long-acting medications for the treatment of hyperkinetic disorders -: A systematic review and European treatment guideline.: Part 1:: Overview and recommendations [J].
Banaschewski, Tobias ;
Coghill, David ;
Santosh, Paramala ;
Zuddas, Alessandro ;
Asherson, Philip ;
Buitelaar, Jan ;
Danckerts, Marina ;
Doefner, Manfred ;
Faraone, Stephen V. ;
Rothenberger, Aribert ;
Sergeant, Joseph ;
Steinhausen, Hans-Christoph ;
Sonuga-Barke, Edmund J. S. ;
Taylor, Eric .
ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 2008, 36 (02) :81-95
[3]   Methylphenidate prescriptions in the city of Cologne: Overrepresentation of privately insured patients - Results of an analysis based on prescription data [J].
Bessou, H. ;
Zeeb, H. ;
Puteanus, U. .
GESUNDHEITSWESEN, 2007, 69 (05) :292-296
[4]   Differential Effects of Predictors on Methylphenidate Initiation and Discontinuation Among Young People with Newly Diagnosed Attention-Deficit/Hyperactivity Disorder [J].
Chen, Chuan-Yu ;
Yeh, Hsueh-Han ;
Chen, Kuang-Hung ;
Chang, I-Shou ;
Wu, Erin Chia-Hsuan ;
Lin, Keh-Ming .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (03) :265-273
[5]  
CHMP, 2009, EL REC INCL SUMM PRO
[6]   Osmotic, controlled-release methylphenidate for the treatment of ADHD [J].
Coghill, David ;
Seth, Sarah .
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (15) :2119-2138
[7]   How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample - results of the BELLA study [J].
Doepfner, Manfred ;
Breuer, Dieter ;
Wille, Nora ;
Erhart, Michael ;
Ravens-Sieberer, Ulrike .
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2008, 17 (Suppl 1) :59-70
[8]  
Dopfner M, 2007, LEITLINIEN DTSCH GES, P237
[9]   Effects of Methylphenidate on Intelligence and Attention Components in Boys with Attention-Deficit/Hyperactivity Disorder [J].
Hellwig-Brida, Susanne ;
Daseking, Monika ;
Keller, Ferdinand ;
Petermann, Franz ;
Goldbeck, Lutz .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (03) :245-253
[10]   Utilization Patterns of Stimulants in ADHD in the Medicaid Population: A Retrospective Analysis of Data from the Texas Medicaid Program [J].
Lawson, Kenneth A. ;
Johnsrud, Michael ;
Hodgkins, Paul ;
Sasane, Rahul ;
Crismon, M. Lynn .
CLINICAL THERAPEUTICS, 2012, 34 (04) :944-956